GLP-1 medicines
Checked Oct 11, 2026 · 20 sources checked
GLP-1 medicines act on the receptor for GLP-1, a hormone the gut releases after eating. They boost insulin when blood sugar is high, slow stomach emptying and reduce appetite. Older injectables include exenatide, liraglutide and dulaglutide; semaglutide is newer. Tirzepatide also acts on a second gut-hormone receptor, and the experimental retatrutide on three. Orforglipron (Foundayo) is a pill approved for weight management in April 2026. In the US, several are approved for type 2 diabetes, and some for weight management; retatrutide is not. The most common side effects are gastrointestinal. Labels for semaglutide, tirzepatide and orforglipron carry a boxed thyroid-tumor warning based on rodent studies of GLP-1 drugs, plus pancreatitis and gallbladder warnings. One drug's results are not assumed to apply to the whole group.
Education only, not medical advice. Talk to a clinician about your own situation.
Attention and coverage on this topic — not proof. Receipts below.
NPR · Oct 10, 2026
PBS · Oct 7, 2026
Reuters · Oct 7, 2026
Most of the attention sits on the individual drug pages. In September 2026, English Wikipedia's Semaglutide, Retatrutide and Tirzepatide articles had 38,937, 35,139 and 34,205 views, against 863 for the class article. Research volume is high: 304 PubMed records mentioning GLP-1 receptor agonists in the 30 days to Oct 11 2026. ClinicalTrials.gov lists 635 recruiting, active or not-yet-recruiting studies that name a GLP-1 medicine as an intervention. That reflects steady scale, not a spike.
In people with type 2 diabetes, a meta-analysis of eight placebo-controlled cardiovascular outcome trials (60,080 patients) found that GLP-1 receptor agonists as a group reduced major cardiovascular events by 14% (hazard ratio 0.86), along with all-cause death, heart-failure hospitalization and a kidney composite.
Do GLP-1 medicines reduce risky drinking in people with alcohol use disorder?
If SURMOUNT-MMO (NCT05556512) or TRIUMPH-Outcomes (NCT06383390) is null on its primary cardiovascular endpoint, we would say obesity-related cardiovascular benefit is drug-specific (shown for semaglutide only) rather than a property of the class.
If CRAVE (NCT07218354) is null on its primary endpoint, the hub will say the alcohol-use-disorder signal was not confirmed in a large trial.
Word on the street
Who's covering it lately. Coverage means people are talking about it; it isn't evidence, and it never changes our read.
- NPR · Oct 10, 2026Read the coverage ↗
- PBS · Oct 7, 2026Read the coverage ↗
- Reuters · Oct 7, 2026Read the coverage ↗
- The New York Times · Sep 22, 2026Read the coverage ↗
For the pros: claims, studies and receipts20 sources · tap to open
6 reviewed claim records · 20 linked source receipts Inspect source receipts
Maturity: source checked
In people with type 2 diabetes, a meta-analysis of eight placebo-controlled cardiovascular outcome trials (60,080 patients) found that GLP-1 receptor agonists as a group reduced major cardiovascular events by 14% (hazard ratio 0.86), along with all-cause death, heart-failure hospitalization and a kidney composite.
Adults with type 2 diabetes (8 CVOTs) · Outcome: MACE; all-cause mortality; HF hospitalization; kidney compositeConfidence applies to this claim and context.
Checked facts
- In people with type 2 diabetes, a meta-analysis of eight placebo-controlled cardiovascular outcome trials (60,080 patients) found that GLP-1 receptor agonists as a group reduced major cardiovascular events by 14% (hazard ratio 0.86), along with all-cause death, heart-failure hospitalization and a kidney composite. PMID 34425083 ↗
- In adults with obesity and no diabetes, average weight loss versus placebo over 68-72 weeks differed by drug: semaglutide injection 14.9% vs 2.4% (STEP 1), tirzepatide 15.0-20.9% vs 3.1% (SURMOUNT-1), orforglipron 7.5-11.2% vs 2.1% (ATTAIN-1). Only one trial compared two of these directly (tirzepatide vs semaglutide, SURMOUNT-5), so cross-trial numbers should not be ranked. PMID 33567185 ↗
- In people without diabetes, the completed placebo-controlled trial showing fewer heart attacks, strokes and cardiovascular deaths is SELECT: semaglutide in adults with established cardiovascular disease and overweight or obesity. Tirzepatide separately reduced a heart-failure outcome in people with HFpEF and obesity (SUMMIT). Neither result is assumed to apply to the other drugs. PMID 37952131 ↗
- Liraglutide, an earlier GLP-1 drug, lowered the combined rate of cardiovascular death, heart attack or stroke versus placebo in type 2 diabetes (13.0% vs 14.9%; hazard ratio 0.87) over a median of 3.8 years. PMID 27295427 ↗
- Not every hoped-for benefit has held up. In two phase 3 trials in early Alzheimer's disease, oral semaglutide did not slow decline versus placebo. PMID 41865758 ↗
- Stopping treatment matters. In a randomized withdrawal trial, people switched from tirzepatide to placebo regained much of the weight they had lost. In another trial, people who switched from an injectable to the oral GLP-1 drug orforglipron kept more of their weight loss than those switched to placebo. That trial had no group that stayed on injections. PMID 38078870 ↗
Attention describes reviewed public attention, evidence shows study types, and confidence applies only to the stated claim. There is no overall score.
Claims
Would change this claim: If SURMOUNT-MMO (NCT05556512) or TRIUMPH-Outcomes (NCT06383390) is null on its primary cardiovascular endpoint, we would say obesity-related cardiovascular benefit is drug-specific (shown for semaglutide only) rather than a property of the class.
Source: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. · PMID 34425083 · Lancet Diabetes Endocrinol · Abstract, Findings: MACE HR 0.86 (95% CI 0.80-0.93); mortality HR 0.88; HF hospitalization HR 0.89; kidney HR 0.79 · Verify ↗Mapped studies / experiment families
One experiment counts once, even with several registrations or publications. Counts above describe the headline claim.
No reviewed experiment families mapped yet.
Studies & active trials
Only papers and registered trials an editor reviewed for this page. Being listed is not a finding; the claims above say what they show.
What still isn't settled?
Do GLP-1 medicines reduce risky drinking in people with alcohol use disorder?
Three small randomized trials of semaglutide report improvements in some drinking outcomes but not others; none is large or long enough to settle it, and evidence for other GLP-1 drugs is thinner.
What would answer it: The primary result of the VA CRAVE trial of semaglutide (NCT07218354; 622 veterans; estimated primary completion 2029-03). Class-wide claims would need trials of more than one drug.
Already settled for type 2 diabetes: pooled across eight placebo-controlled outcome trials, GLP-1 drugs as a group lowered major cardiovascular events. Results for individual drugs varied, so each drug page reports its own trials.